Double-blind study shows HIV vaccine not effective in viral suppression

December 7, 2017 by Bob Yirka, Medical Xpress report

Credit: National Cancer Institute
(Medical Xpress)—A large team of researchers from the U.S. and Canada has conducted a randomized double-blind study of the effectiveness of an HIV vaccine and has found it to be ineffective in suppressing the virus. In their paper published in Science Translational Medicine, the group describes the study, what they found and why they believe their work has provided the medical research community a valuable lesson on the importance of placebo-controlled studies. Michael Nelson with Walter Reed Army Institute of Research offers a FOCUS piece on the work done by the team in the same journal issue.

A lot of research has gone into curing people infected with HIV, but that goal has still not been achieved. In the meantime, (ART) drugs allow people infected with the virus to live an almost normal existence. But the goal of developing a remains. One approach has been to provide a two-stage attack, injecting patients first with a HIV multi-antigen and a DNA plasmid encoding human interleukin proteins and then following up with a booster containing a . The idea behind this approach is to nudge the immune system into learning how to combat the virus so that ART drugs are no longer needed. But, the approach has not been proven. In this new effort, the research team conducted a study designed to test the effectiveness of the vaccine.

The study consisted of enlisting the assistance of 30 early-stage patients (one dropped out) with HIV infections who were already being treated with ARTs and assigning them to one of two groups—14 patients got the vaccine while 15 got a placebo. Injections took place at 0, 4, 12, 24, 36 and 48 weeks. ART drug administration was halted for all of the volunteers starting at week 56 and lasting until week 72. All of the volunteers were tested regularly throughout the study for viral loads, a measure of how well the body, along with ARTs and/or the vaccine, was working to suppress the virus.

The researchers report that they found no measurable increase in effectiveness in any of the volunteers who were given the vaccine. They also report that they were surprised to see that four of the volunteers who had received the placebo had lower than normal viral loads for a short time. This finding was particularly important, the researchers note, because it showed that if the study not been conducted with placebos, the results would have showed that the vaccine had worked to a limited extent. And that, Nelson notes, is the real lesson learned from this study.

Explore further: Trials show inactivated Zika virus vaccine is safe and immunogenic

More information: Michael C. Sneller et al. A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aan8848

Abstract
Despite substantial clinical benefits, complete eradication of HIV has not been possible using antiretroviral therapy (ART) alone. Strategies that can either eliminate persistent viral reservoirs or boost host immunity to prevent rebound of virus from these reservoirs after discontinuation of ART are needed; one possibility is therapeutic vaccination. We report the results of a randomized, placebo-controlled trial of a therapeutic vaccine regimen in patients in whom ART was initiated during the early stage of HIV infection and whose immune system was anticipated to be relatively intact. The objectives of our study were to determine whether the vaccine was safe and could induce an immune response that would maintain suppression of plasma viremia after discontinuation of ART. Vaccinations were well tolerated with no serious adverse events but produced only modest augmentation of existing HIV-specific CD4+ T cell responses, with little augmentation of CD8+ T cell responses. Compared with placebo, the vaccination regimen had no significant effect on the kinetics or magnitude of viral rebound after interruption of ART and no impact on the size of the HIV reservoir in the CD4+ T cell compartment. Notably, 26% of subjects in the placebo arm exhibited sustained suppression of viremia (<400 copies/ml) after treatment interruption, a rate of spontaneous suppression higher than previously reported. Our findings regarding the degree and kinetics of plasma viral rebound after ART interruption have potentially important implications for the design of future trials testing interventions aimed at achieving ART-free control of HIV infection.

Related Stories

Trials show inactivated Zika virus vaccine is safe and immunogenic

December 5, 2017
The investigational Zika purified inactivated virus (ZPIV) vaccine was well-tolerated and induced an immune response in participants, according to initial results from three Phase 1 clinical trials. Scientists at the Walter ...

New therapeutic vaccine approach holds promise for HIV remission

November 9, 2016
A study led by researchers at Beth Israel Deaconess Medical Center (BIDMC), in collaboration with scientists at Walter Reed Army Institute of Research (WRAIR), Janssen Vaccines & Prevention B.V., one of the Janssen Pharmaceutical ...

Live attenuated flu vaccine not effective for children in 2015-16

August 10, 2017
(HealthDay)—During the 2015 to 2016 season, influenza vaccines reduced the risk of influenza illness, but the live attenuated vaccine was ineffective among children 2 to 17 years of age, according to a study published in ...

Studies reveal how shingles vaccine should be used in arthritis patients

August 28, 2017
New research indicates that the live varicella-zoster vaccine—which is given to protect against shingles—elicits robust immune responses in patients when administered several weeks prior to the start of treatment with ...

Ebola vaccines provide immune responses after one year

March 14, 2017
Immune responses to Ebola vaccines at one year after vaccination are examined in a new study appearing in the March 14 issue of JAMA.

Pennsylvania firm launches Zika vaccine trial in Puerto Rico

August 29, 2016
A Pennsylvania drug company announced Monday that it has launched a clinical trial of an experimental Zika vaccine in Puerto Rico, the part of the U.S. hardest hit by the mosquito-borne virus.

Recommended for you

Gene plays critical role in noise-induced deafness

October 19, 2018
In experiments using mice, a team of UC San Francisco researchers has discovered a gene that plays an essential role in noise-induced deafness. Remarkably, by administering an experimental chemical—identified in a separate ...

Functional engineered oesophagus could pave way for clinical trials 

October 18, 2018
The world's first functional oesophagus engineered from stem cells has been grown and successfully transplanted into mice, as part of a pioneering new study led by UCL.

New findings cast light on lymphatic system, key player in human health

October 16, 2018
Scientists at the Oklahoma Medical Research Foundation have broken new ground in understanding how the lymphatic system works, potentially opening the door for future therapies.

New model suggests cuffless, non-invasive blood pressure monitoring possible using pulse waves

October 16, 2018
A large team of researchers from several institutions in China and the U.S. has developed a model that suggests it should be possible to create a cuffless, non-invasive blood pressure monitor based on measuring pulse waves. ...

Age-related increase in estrogen may cause common men's hernia

October 16, 2018
An age-related increase in estrogen may be the culprit behind inguinal hernias, a condition common among elderly men that often requires corrective surgery, according to a Northwestern Medicine study was published Oct. 15 ...

Income and wealth affect the mental health of Australians, study shows

October 16, 2018
Australians who have higher incomes and greater wealth are more likely to experience better mental health throughout their lives, new research led by the Bankwest Curtin Economics Centre has found.

3 comments

Adjust slider to filter visible comments by rank

Display comments: newest first

Bart_A
1 / 5 (2) Dec 07, 2017
The best way to avoid HIV? Just don't ever get involved in any extramarital sex. Ever. It is the most sure way to keep sexual health and the love lights burning.

Spoken from experience.
jhnycmltly
not rated yet Dec 07, 2017
Targeting the iron is working well.
"suppressed the virus in patients during treatment and for at least eight weeks after the drug was stopped, according to results of a clinical pilot trial " "The anti-HIV effect of deferiprone persisted after the drug was stopped -- "an effect quite different from all current antiretrovirals," "
barakn
4 / 5 (1) Dec 10, 2017
Bart_A, abstinence-only programs and virginity pledges don't delay sexual activity and lower the use of contraceptives, so your personal experience is an irrelevant anecdote. http://www.advoca...programs
But surely you don't HIV to spread amongst gay people and are therefore advocating for gay marriage, right?

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.